Akebia Therapeutics (AKBA) Receivables (2013 - 2026)
Akebia Therapeutics (AKBA) recorded Receivables of $58.88 million in Q2 2026, down 57.4% from $138.21 million a year earlier and down 8.3% from the prior quarter.
Akebia Therapeutics (AKBA) Receivables (2013 - 2026) Analysis & Trends
At the end of FY2025, Akebia Therapeutics reported Receivables of $49.62 million, up 36.4% from FY2024.
- Annual Receivables has a five-year compound annual growth rate of 9.4% (FY2020 to FY2025).
- Across earlier years, Receivables came in at $36.38 million in FY2024 (-14.7%), $42.62 million in FY2023 (-0.8%), $42.97 million in FY2022 (-42.7%) and $74.98 million in FY2021 (+137.1%).
- Quarterly Receivables has ranged from $19.15 million in Q1 2023 to $148.18 million in Q2 2022 over the past five years.
- On a year-over-year basis, Receivables rose in six of the last eight quarters, with growth averaging 71.2%.
- Peak year-over-year performance for Receivables in the last five years was growth of 337.5% in Q2 2025, against a decline of 86.4% in Q2 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $64.2 million (Q1 2026), $49.62 million (Q4 2025) and $69.28 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 15.68 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 5.06 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 2.13 Bn |
| 10 | Akebia Therapeutics | 241.85 Mn | -427.63 Mn | 38.70 Mn | 58.88 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 58.88 Mn |
| Mar 31, 2026 | 64.20 Mn |
| Dec 31, 2025 | 49.62 Mn |
| Sep 30, 2025 | 69.28 Mn |
| Jun 30, 2025 | 138.21 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 36.38 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 31.59 Mn |
| Mar 31, 2024 | 29.31 Mn |
| Dec 31, 2023 | 42.62 Mn |
| Sep 30, 2023 | 23.07 Mn |
| Jun 30, 2023 | 20.10 Mn |
| Mar 31, 2023 | 19.15 Mn |
| Dec 31, 2022 | 42.97 Mn |
| Sep 30, 2022 | 30.75 Mn |
| Jun 30, 2022 | 148.18 Mn |
| Mar 31, 2022 | 93.64 Mn |
| Dec 31, 2021 | 74.98 Mn |
| Sep 30, 2021 | 74.55 Mn |
Akebia Therapeutics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=AKBA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();